Candriam SCA Portfolio holdings
Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$98.2M |
| 2 |
Meta Platforms (Facebook)
META
|
+$82.9M |
| 3 |
ServiceNow
NOW
|
+$70.4M |
| 4 |
Intel
INTC
|
+$58.4M |
| 5 |
Salesforce
CRM
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$102M |
| 2 |
Palo Alto Networks
PANW
|
+$102M |
| 3 |
AbbVie
ABBV
|
+$68.9M |
| 4 |
Amazon
AMZN
|
+$57M |
| 5 |
NVIDIA
NVDA
|
+$54.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.06% |
| 2 | Healthcare | 24.01% |
| 3 | Financials | 9.02% |
| 4 | Communication Services | 7.08% |
| 5 | Consumer Discretionary | 6.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
201
Intuit
INTU
$91.3B
| $19M | 0.08% |
68,507
+44,348
| +184% | +$13.9M |
2014 Q4
47 quarters
|
|
202
Newmont
NEM
$118B
| $18.9M | 0.08% |
163,198
-8,309
| -5% | -$930K |
2014 Q4
47 quarters
|
|
203
Compass Pathways
CMPS
$1.28B
| $18.9M | 0.08% |
1,510,695
+236,417
| +19% | +$3.14M |
2026 Q2
1 quarter
|
|
204
Boston Scientific
BSX
$64.3B
| $18.9M | 0.08% |
430,284
+62,799
| +17% | +$2.91M |
2014 Q4
47 quarters
|
|
205
Trevi Therapeutics
TRVI
$1.95B
| $18.8M | 0.08% |
1,308,104
+341,885
| +35% | +$5.88M |
2026 Q1
2 quarters
|
|
206
Idexx Laboratories
IDXX
$55.5B
| $18.7M | 0.08% |
35,686
+1,168
| +3% | +$640K |
2018 Q2
33 quarters
|
|
207
Vera Therapeutics
VERA
$2.03B
| $18.4M | 0.08% |
568,560
+100,461
| +21% | +$3.51M |
2024 Q1
10 quarters
|
|
208
Mineralys Therapeutics
MLYS
$1.36B
| $18.4M | 0.08% |
729,902
-127,135
| -15% | -$3.46M |
2024 Q4
7 quarters
|
|
209
Starbucks
SBUX
$121B
| $18.3M | 0.08% |
193,958
+40,466
| +26% | +$4.18M |
2014 Q4
47 quarters
|
|
210
Amphenol
APH
$193B
| $18.1M | 0.08% |
213,980
+43,562
| +26% | +$3.51M |
2016 Q1
42 quarters
|
|
211
Citizens Financial Group
CFG
$27.4B
| $18.1M | 0.08% |
282,513
+209,060
| +285% | +$14.7M |
2016 Q1
42 quarters
|
|
212
Sysco
SYY
$38B
| $17.8M | 0.08% |
227,780
+146,864
| +182% | +$12.1M |
2014 Q4
47 quarters
|
|
213
Praxis Precision Medicines
PRAX
$9.17B
| $17.8M | 0.08% |
60,856
| – | – |
2024 Q3
8 quarters
|
|
214
Zenas BioPharma
ZBIO
$1.9B
| $17.7M | 0.08% |
+654,833
| New | +$20.2M |
2026 Q3
0 quarters
|
|
215
Synchrony
SYF
$22.5B
| $17.7M | 0.08% |
247,927
-259,763
| -51% | -$19.8M |
2015 Q4
43 quarters
|
|
216
Magna International
MGA
$16B
| $17.2M | 0.08% |
269,045
+2,138
| +0.8% | +$142K |
2014 Q4
47 quarters
|
|
217
Xenon Pharmaceuticals
XENE
$3.98B
| $17.2M | 0.08% |
461,498
-1,270
| -0.3% | -$75.4K |
2021 Q2
21 quarters
|
|
218
Air Products & Chemicals
APD
$70.5B
| $17.1M | 0.08% |
61,129
+75
| +0.1% | +$22.3K |
2016 Q1
42 quarters
|
|
219
Synopsys
SNPS
$87.2B
| $17M | 0.08% |
38,905
-8,995
| -19% | -$3.67M |
2019 Q2
29 quarters
|
|
220
Sandisk
SNDK
$126B
| $16.9M | 0.07% |
+9,660
| New | +$15.1M |
2026 Q3
0 quarters
|
|
221
Celldex Therapeutics
CLDX
$2.26B
| $16.9M | 0.07% |
518,476
+37,351
| +8% | +$1.43M |
2026 Q1
2 quarters
|
|
222
MBX Biosciences
MBX
$2.78B
| $16.6M | 0.07% |
281,493
-8,400
| -3% | -$526K |
2026 Q1
2 quarters
|
|
223
Kimco Realty
KIM
$17B
| $16.1M | 0.07% |
721,866
+180,443
| +33% | +$4.39M |
2026 Q1
2 quarters
|
|
224
Medpace
MEDP
$18.3B
| $16.1M | 0.07% |
25,633
-243
| -0.9% | -$142K |
2024 Q1
10 quarters
|
|
225
American Water Works
AWK
$29.8B
| $16M | 0.07% |
123,503
-121,659
| -50% | -$16.5M |
2016 Q2
41 quarters
|
|
Similar funds
Candriam SCA's Q3 2026 Portfolio in Review
As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.
- Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
- Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
- Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
- Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
- Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
- Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
- Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.
Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.